

Dolutegravir (sodium)/lamivudine/tenofovir
disoproxil fumarate
50 mg/300 mg/300 mg tablets
(Cipla Ltd.), HA702

WHOPAR Part 2

April 2025


All accepted presentations of [HA702 trade name]*

See:

<https://extranet.who.int/prequal/medicines/prequalified/finished-pharmaceutical-products>

Search for WHO reference number (as provided in the header).

Appearance



* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.
Page 1 of 1